Pegylation: engineering improved pharmaceuticals for enhanced therapy (Q34782103)

4 August 2017

1 reference

title

Pegylation: engineering improved pharmaceuticals for enhanced therapy (English)

1 reference

4 August 2017

G Molineux

1

1 reference

4 August 2017

publication date

1 April 2002

1 reference

4 August 2017

published in

Cancer Treatment Reviews

1 reference

4 August 2017

volume

28 Suppl A

1 reference

4 August 2017

page(s)

13-16

1 reference

Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Characterization and stability of N-terminally PEGylated rhG-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Peptide and protein PEGylation: a review of problems and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Novel effects with polyethylene glycol modified pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2980004-4

7 January 2021

10.1016/S0305-7372(02)80004-4

Identifiers

DOI

1 reference

4 August 2017

1 reference